Experienced in Interstitial Nephritis

Dr. Pierluigi Porcu

Hematology Oncology | Oncology | Hematology
Jefferson University Physicians
925 Chestnut St, Suite 3, 
Philadelphia, PA 
Experienced in Interstitial Nephritis
Jefferson University Physicians
925 Chestnut St, Suite 3, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pierluigi Porcu is a Hematologist Oncology specialist and an Oncologist in Philadelphia, Pennsylvania. Dr. Porcu is rated as an Experienced provider by MediFind in the treatment of Interstitial Nephritis. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 155 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Interstitial Nephritis.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in KY
Hospital Affiliations
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO

Locations

JEFFERSON UNIVERSITY PHYSICIANS
925 Chestnut St, Suite 3, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Durvalumab, Lenalidomide
Study Phase: Phase 1/Phase 2
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma
Enrollment Status: Completed
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: Nivolumab+EPOCH
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 1
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Lenalidomide
Study Phase: Phase 1
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Biological
Study Phase: Phase 2
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Enrollment Status: Terminated
Publish Date: March 13, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 10 Less Clinical Trials

152 Total Publications

Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression.
Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression.
Journal: Neuro-oncology advances
Published: June 27, 2025
Similar Doctors
Andres Ferber
Advanced in Interstitial Nephritis
Dr. Andres Ferber
Hematology Oncology | Hematology | Oncology
Advanced in Interstitial Nephritis
Dr. Andres Ferber
Hematology Oncology | Hematology | Oncology

Jefferson Torresdale Hospital

10800 Knights Road, 
Philadelphia, PA 
 (12.4 miles away)
215-890-3030
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andres Ferber is a Hematologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Ferber is rated as a Distinguished provider by MediFind in the treatment of Interstitial Nephritis. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Cryoglobulinemia, Familial Mixed Cryoglobulinemia, and Chronic Lymphocytic Leukemia (CLL). Dr. Ferber is currently accepting new patients.

Experienced in Interstitial Nephritis
Dr. Michael J. Styler
Hematology Oncology | Hematology | Oncology
Experienced in Interstitial Nephritis
Dr. Michael J. Styler
Hematology Oncology | Hematology | Oncology

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (3.8 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances

Michael Styler is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Styler is rated as a Distinguished provider by MediFind in the treatment of Interstitial Nephritis. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Multiple Myeloma, Colorectal Cancer, Bone Marrow Transplant, and Bone Marrow Aspiration.

Pooja Suresh
Experienced in Interstitial Nephritis
Dr. Pooja Suresh
Hematology Oncology | Hematology | Oncology
Experienced in Interstitial Nephritis
Dr. Pooja Suresh
Hematology Oncology | Hematology | Oncology

Abington Cancer Care Specialists

Willow Grove, PA 
 (14.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pooja Suresh is a Hematologist and an Oncologist in Willow Grove, Pennsylvania. Dr. Suresh is rated as an Advanced provider by MediFind in the treatment of Interstitial Nephritis. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Cryoglobulinemia, and Familial Mixed Cryoglobulinemia. Dr. Suresh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Porcu's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile